ライフサイエンスコーパス: guanfacine

1 roved working memory with the a2A-NA agonist Guanfacine.

2 s of alpha(2A)AR evoked by clonidine than by guanfacine.

3 sulted in loss of the beneficial response to guanfacine.

4 entify the molecular target of the action of guanfacine.

5 o receive either daily placebo (12 M/7 F) or guanfacine (2 or 3 mg) (15 M/6 F) for 3 weeks.

6 Here, we show that guanfacine, a noradrenergic agonist that modulates dorso

7 Guanfacine, a noradrenergic alpha2a agonist, reduced tob

8 ic animals responded to both amphetamine and guanfacine, an alpha2A adrenergic receptor agonist.

9 Lastly, inhibiting cAMP generation with guanfacine, an alpha2A-noradrenergic agonist, normalized

10 tex and identify the molecular substrate for guanfacine and novel therapeutic interventions.

11 Guanfacine appears to be a safe and effective treatment

12 Extended-release guanfacine appears to be safe and effective for reducing

13 The modal dose of guanfacine at week 8 was 3 mg/day (range: 1-4 mg/day), a

14 Systemic administration of guanfacine blocked the increase in immobility in respons

15 on-Improvement scale) was 50% (15 of 30) for guanfacine compared with 9.4% (3 of 32) for placebo.

16 Guanfacine did, however, reduce sympathetic tone as well

17 In an initial dose-testing phase we found a Guanfacine dose that increased performance accuracy, dec

18 Monkeys treated with higher guanfacine doses also appeared less disinhibited, sugges

19 In slices from these mice, we found that guanfacine enhanced, rather than suppressed, optogenetic

20 The alpha2-AR agonist guanfacine enhances prefrontal cortical functions in rat

21 l translation from animals to humans include guanfacine for the treatment of ADHD and related PFC dis

22 o the successful translation of prazosin and guanfacine for treating stress-related disorders.

23 igh doses of the alpha-2A adrenergic agonist guanfacine (GFC) to aged monkeys has been shown to impro

24 , we test this hypothesis using clonidine or guanfacine (GFC), another alpha-2 agonist, in a model of

25 d hyperactivity index improved by 27% in the guanfacine group and 21% in the placebo group, not a sig

26 The guanfacine group showed a 43.6% decline in scores on the

27 For subjects in the guanfacine group, blood pressure declined in the first 4

28 Tic severity decreased by 31% in the guanfacine group, compared to 0% in the placebo group.

29 sed by 22% and omission errors by 17% in the guanfacine group, compared with increases of 29% in comm

30 Guanfacine had no effect on PTSD symptoms, subjective sl

31 he effects of the alpha2 adrenergic agonist, guanfacine HCl, on responses to stress and drug cue in a

32 But it has been unclear whether Guanfacine improves specific attention and learning mech

33 The findings suggest further evaluation of guanfacine in the treatment of cocaine use disorder with

34 s study evaluated the efficacy and safety of guanfacine in treating children with tic disorders and a

35 Guanfacine-induced normalization of dopamine signaling m

36 The local application of guanfacine into either the prelimbic cortex or the ventr

37 Extended-release guanfacine is approved for children with attention defic

38 dopamine (bromocriptine) and norepinephrine (guanfacine) manipulations did not improve performance or

39 le pharmacotherapy were randomly assigned to guanfacine (N=29) versus placebo (N=34).

40 5 years [SD=2.25]) were randomly assigned to guanfacine (N=30) or placebo (N=32) for 8 weeks.

41 e findings highlight sex-specific effects of guanfacine on drug craving, anxiety, and negative mood w

42 The effects of guanfacine on performance of the delayed alternation tas

43 extended-release alpha2-adrenergic agonists guanfacine or clonidine (no studies).

44 ssigned to receive 8 weeks of treatment with guanfacine or placebo under double-blind conditions.

45 Six of the hits (guanfacine, quinidine, xylometazoline, oxymetazoline, fe

46 We found that the alpha(2A)-AR agonist guanfacine selectively inhibited this PBN input to the B

47 Guanfacine significantly attenuated cocaine craving, alc

48 One guanfacine subject with sedation withdrew at week 4.

49 ated by the centrally acting alpha2a agonist guanfacine, suggesting a role of increased sympathetic t

50 mulations, atomoxetine, and extended-release guanfacine to improve symptoms of ADHD in adolescents.

51 e in baseline BPND from the untreated to the guanfacine-treated condition.

52 e and was compared between the untreated and guanfacine-treated conditions.

53 Four guanfacine-treated subjects (13.3%) and four placebo sub

54 A subset (n=12) then underwent guanfacine treatment (3 mg/day for 3 weeks) and the set

55 Guanfacine treatment attenuated amphetamine-induced DA r

56 Chronic guanfacine treatment reduced [(11)C]FLB457 BPND in tobac

57 athetic neurons in response to clonidine and guanfacine, two drugs used for treatment of hypertension

58 double-blind, randomized controlled trial of guanfacine versus placebo for posttraumatic stress disor

59 After 8 weeks of treatment, guanfacine was associated with a mean improvement of 37%

60 Guanfacine was associated with a number of side effects.

61 Guanfacine was associated with insignificant decreases i

62 randomized clinical trial, extended-release guanfacine was compared with placebo in children with AS

63 Guanfacine was then used in all local injection studies.

64 The positive effects of guanfacine were associated with extended ability to main

65 Nine of 17 subjects who received guanfacine were blindly rated on the Clinical Global Imp

66 Guanfacine, which is an alpha-2 agonist with a higher af

67 Ca(2+) current suppression by clonidine than guanfacine, which paralleled a more marked receptor phos

68 mine release before and after treatment with guanfacine with [(11)C]FLB457, a dopamine D2/D3 receptor

69 faster feature-based reversal learning with Guanfacine with single-subject computational modeling.